Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 11 Mar 2023
Acadia Pharmaceuticals announces US FDA approval of Daybue (trofinetide) for the treatment of Rett syndrome in adult and paediatric patients two years of age and older
10 March 2023 - Company expects Daybue to be available by the end of April 2023. ...
Posted by Michael Wonder on 10 Mar 2023
Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices.
10 March 2023 - By law, Medicare will have to take a medication’s efficacy and its research and development costs ...
Posted by Michael Wonder on 10 Mar 2023
Pfizer’s Zavzpret (zavegepant) migraine nasal spray receives FDA approval
10 March 2023 - Zavzpret is the first and only calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment ...
Posted by Michael Wonder on 10 Mar 2023
Alberta’s import of children’s medication to cost taxpayers $80 million
9 March 2023 - Alberta taxpayers are on the hook for $80 million, after Health Minister Jason Copping finally revealed ...
Posted by Michael Wonder on 10 Mar 2023
ICER to assess gene therapy for metachromatic leukodystrophy
9 March 2023 - Report will be subject of CTAF meeting in September 2023; draft scoping document open to public ...
Posted by Michael Wonder on 10 Mar 2023
Will NZ neurological drug Trofinetide for Rett syndrome get US FDA approval and make history?
10 March 2023 - Kiwi scientists may be about to make New Zealand history, with a breakthrough treatment on the ...
Posted by Michael Wonder on 10 Mar 2023
Astellas and Seagen announce China's National Medical Products Administration accepts biologics license application for enfortumab vedotin in certain patients with locally advanced or metastatic urothelial cancer
10 March 2023 - Clinical data submitted are consistent with global data and support enfortumab vedotin as a platinum-free option ...
Posted by Michael Wonder on 09 Mar 2023
Samsung Bioepis launches Lucentis biosimilar in Canada, Germany
5 March 2023 - According to industry sources on Sunday, SB11 was introduced to the Canadian market last Wednesday through its ...
Posted by Michael Wonder on 09 Mar 2023
Swissmedic issues unlimited authorisation for booster dose of Moderna's bivalent COVID-19 Original/Omicron BA.4-5 vaccine
8 March 2023 - Spikevax bivalent Original/Omicron BA.4-5 mRNA vaccine authorised for people aged 18 and over. ...
Posted by Michael Wonder on 09 Mar 2023
AMA urges immediate action to save patients on PBS medicines
9 March 2023 - The AMA has urged all members of the Federal Parliament to support the AMA’s campaign to bring ...
Posted by Michael Wonder on 09 Mar 2023
Patent system key to lower drug prices, experts say
9 March 2023 - Following the Biden administration’s progress towards lowering prescription drug prices with Medicare price negotiations, some industry ...
Posted by Michael Wonder on 09 Mar 2023
New drugs are coming to market at sky-high prices
9 March 2023 - Trend follows rising pressure on companies to rein in repeat or annual price hikes for older drugs/ ...
Posted by Michael Wonder on 09 Mar 2023
Mallinckrodt announces reimbursement approval in Japan for the Celllex extracorporeal photopheresis system for the treatment of chronic graft versus host disease
9 March 2023 - Cellex ECP is now available for reimbursement in Japan for patients who are steroid-resistant or intolerant ...
Posted by Michael Wonder on 09 Mar 2023
CADTH recommends reimbursement for BioCryst’s Orladeyo (berotralstat) for the routine prevention of attacks in hereditary angioedema patients in Canada
8 March 2023 - BioCryst Pharmaceuticals today announced that the CADTH Canadian Drug Expert Committee has issued a positive recommendation ...
Posted by Michael Wonder on 09 Mar 2023
Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails
9 March 2023 - A decade ago, I had pegged gene and cell therapies as the next frontier. As an ...